MOMO'S BREAKOUT BOARD

[growacet]

A biotech stock that nobody is talking about $RVXCF$

Its a Canadian biotech, not listed on a US exchange, hence the reason its OTC in the states. In Canada it trades on the big Toronto board under the symbol RVX.TO

The Market Cap is about $700 million USD, just under $1 billion Canadian. The trading is light, you won't find millions of shares trading each day...not even if you combine the US OTC trading with the Canadian TSX trading. Of late its been a couple hundred thousand shares total combining the two, sometimes less than that.

Despite the light volumes the stock has climbed this past year, from under $1 US to over $3...the 52 week high is actually over $4, but that was a couple days ago and it looks like it was the result of someone slamming the ask right at the opening bell. My expectation is it will get back over $4 and keep going....

Why???

Because their lead compound Apabetalone is wrapping up a phase 3 trial with top-line results expected sometime this summer. Apabetalone is an epigenetic drug....which means it operates above the genetic level. Basically it acts as almost a dimmer switch, to turn genes in a diseased state to a non-diseased state.

The trial is called BETonMACE and its been running since 2015....the goal of the trial is to try and prove that Apabetalone will have a positive impact on the time to the first occurrence of Major Adverse Cardiac Events, or MACE for short, in patients who have: Diabetes, Low HDL (good) cholestorol and a recent Adverse Cardiac Event...within the last 90 days before dosing.

The secondary end points centre around Kidney Disease and Cognition. There is evidence from earlier trials to suggest that Apabetalone improves kidney function in areas like eGFR as well on people suffering from cognitive impairment which can result from Alzheimer's and Vascular Dementia.

Its worth doing some research and DD on imo....I think a pre-results market cap of $2 billion is not out of the question....and if they hit on all 3 indications, MACE reduction in Diabetes patients as well as improving Kidney function and cognition....then I believe it will explode...Biogen's failed Alzheimer's drug Aducanumab had a pipeline value of $16 billion USD before it was halted for lack of efficacy.

Not risk free, nothing is of course....reply to this post with any questions and I will try to answer.

Here's a link to a Seeking Alpha blog post I put up....

https://seekingalpha.com/instablog/15663412-joe_retail/5302150-resverlogix-keeps-climbing-high-can-go